Alnylam Pharmaceuticals
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell ALNY and other ETFs, options, and stocks.About ALNY
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R.
ALNY Key Statistics
Stock Snapshot
Alnylam Pharmaceuticals(ALNY) stock is priced at $313.83, giving the company a market capitalization of 41.27B. It carries a P/E multiple of 129.29.
During the trading session on 2026-05-01, Alnylam Pharmaceuticals(ALNY) shares reached a daily high of $333.50 and a low of $287.00. At a current price of $313.83, the stock is +9.3% higher than the low and still -5.9% under the high.
Trading activity shows a volume of 2.19M, compared to an average daily volume of 1.22M.
The stock's 52-week range extends from a low of $245.96 to a high of $495.55.
The stock's 52-week range extends from a low of $245.96 to a high of $495.55.
ALNY News
Alnylam Pharmaceuticals (ALNY) has disclosed a new risk, in the Regulation category. Unlock hedge fund-level data and powerful investing tools for smarter, sha...
Alnylam Pharmaceuticals ((ALNY)) has held its Q1 earnings call. Read on for the main highlights of the call. Claim 55% Off TipRanks Unlock hedge fund-level data...
Image source: The Motley Fool. April 30, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Chief Executive Officer — Yvonne Greenstreet Chief Commercial Officer — Tolga T...
Analyst ratings
68%
of 28 ratingsMore ALNY News
Reports Q1 revenue $1.167B, consensus $1.12B. “2026 is off to a strong start for Alnylam (ALNY) with the end of the first quarter marking one year since the U.S...
Technology Alnylam Pharma Surges After Sales Of Its Biggest Moneymaker Catapult Licensing Alnylam stock jumped early Thursday after the biotech company reported...
(RTTNews) - Alnylam Pharmaceuticals, Inc.(ALNY), an RNAi therapeutics company, on Thursday reported a net income for the first quarter of fiscal 2026, supported...
Investors may be wondering whether Alnylam Pharmaceuticals, at around US$302 a share, still offers value or if most of the opportunity has already been priced i...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.